您好,欢迎来到佐思信息
全国服务热线:
400-009-0050
佐思信息专注支持企业决策
您当前的位置:首页>>研究报告>>再生医学

2016-2021年全球再生医学市场研究报告
Regenerative Medicines Market by Therapy (Cell Therapy, Gene Therapy, Immunotherapy, Tissue Engineering), Product (Cell-Based, Acellular), Application (Orthopaedic & Musculoskeletal Spine, Dermatology, Cardiovascular, Central Nervous System), Region - Global Forecast to 2021

2016-2021年全球再生医学市场研究报告
【报告编号】:No.25789
【发布时间】:2016-07
【关 键 字】:Regenerative Medicine    再生医学        
【报告页数】:160页
【报告价格】:电子版:5650美元
【交付方式】:Email发送或EMS快递
【订购热线】:


400-009-0050(全国24小时服务)
北京:010-82863481
上海:021-64871266 021-64872612

报告目录下载订购协议下载在线咨询

    专业、专注于为企业提供真正有价值的全球市场调查信息,是我们的使命。我们是中国第一家汇集全球众多行业研究机构研究成果的平台,致力于为企业决策提供最有效的市场资讯,特别是为中国企业了解和进入国际市场迈出第一步,提供全面的信息参考,我们跨越语言及时间的障碍,在信息爆炸的当下,努力为客户提供最有价值的全球产业资讯。我们公司也拥有独立的研究机构,聚焦于中国市场的研究,为国内外企业在中国市场大展宏图提供市场研究支持。

• 我们在全球的合作伙伴>>• 我们的研究中心>>

  • 英文摘要
  • 中文摘要
  • 索取简版报告
  • 再生医学行业的相关报告
Report Description
 
The global regenerative medicines market is expected to reach USD 49.41 billion by 2021 from USD 17.06 billion in 2016, at a CAGR of 23.7% during the period of 2016-2021. The global regenerative medicines market is segmented based on product, application, therapy, and region. The cell-based product segment is expected to register the highest growth rate in the regenerative medicines market, by product, during the forecast period. The high growth in this segment is attributed to the variety of products and technologies and rapid increase in the demand of organ transplantation due to which they are most preferred in various applications.
 
Based on therapy, the regenerative medicines market is segmented into cell therapy, gene therapy, immunotherapy, and tissue engineering. The cell therapy segment is expected to account for the largest share of the market in 2016. Increasing funding from various governments and private organizations for carrying out research and development activities related to various cell therapies, growing inclination of the healthcare industry towards stem cell research, and increasing global awareness regarding the benefits of stem cell therapies will drive the growth of this segment.
By application, the segments are orthopaedic & musculoskeletal spine, dermatology, CNS, cardiovascular, oncology, diabetes, and others where cardiovascular and oncology segments are growing rapidly owing to the increasing cases of cancers and cardiovascular diseases especially in the U.S. Over 60,000 stem cell transplants are performed annually globally for the treatment of oncology. 
 
Geographically, the regenerative medicines market is dominated by North America, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). Growth in the North American segment is primarily driven by rising incidences of cancer, increasing government support, expanding biopharmaceutical industry, and launch of new products in the market.
 
The major factors contributing to the growth of the regenerative medicines market include rising regulatory approvals for cell culture-based products, increasing funding for cell-based research, and technological advancements. On the other hand, high cost of research and lack of infrastructure, especially in emerging economies, are the major factors restraining the growth of this market.
 
The major players in this market include Celgene Corporation (U.S.), StemCells, Inc. (U.S.), Corning Incorporated (U.S.), Organogenesis Inc. (U.S.), Acelity (KCI Licensing) (U.S.), Vertex Pharmaceuticals Incorporated (U.S.), among others.
 
Reasons to Buy the Report: 
This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.
 
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on the product portfolios of the top players in the regenerative medicines market. 
• Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and new product launches in the regenerative medicines market 
• Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the regenerative medicines market
• Market Development: Comprehensive information about emerging markets. 
• Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the regenerative medicines market
 
Table of Contents
 
1 INTRODUCTION 14
1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKET DEFINITION 14
1.3 MARKET SCOPE 14
1.3.1 MARKETS COVERED 15
1.3.2 YEARS CONSIDERED FOR THE STUDY 16
1.4 CURRENCY & PRICING 16
1.5 LIMITATIONS 17
1.6 STAKEHOLDERS 17
 
2 RESEARCH METHODOLOGY 18
2.1 MARKET SIZE ESTIMATION 19
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 21
2.3 MARKET SHARE ESTIMATION 23
2.3.1 KEY DATA FROM SECONDARY SOURCES 23
2.3.2 KEY DATA FROM PRIMARY SOURCES 23
2.3.3 ASSUMPTIONS FOR THE STUDY 24
 
3 EXECUTIVE SUMMARY 25
 
4 PREMIUM INSIGHTS 28
4.1 LUCRATIVE OPPORTUNITIES IN THE REGENERATIVE MEDICINES MARKET 28
 
5 MARKET OVERVIEW 31
5.1 INTRODUCTION 31
5.2 MARKET SEGMENTATION 31
5.2.1 REGENERATIVE MEDICINES MARKET SEGMENTATION, BY THERAPY 32
5.2.2 REGENERATIVE MEDICINES MARKET SEGMENTATION, BY PRODUCT 32
5.2.3 REGENERATIVE MEDICINES MARKET SEGMENTATION, BY APPLICATION 33
5.3 MARKET DYNAMICS 34
5.4 DRIVERS 35
5.4.1 GOVERNMENT AND PRIVATE FUNDING TO SUPPORT THE DEVELOPMENT OF REGENERATIVE MEDICINES PRODUCTS 35
5.4.2 INCREASE IN GLOBAL HEALTHCARE EXPENDITURE 35
5.4.3 INCREASE IN AGING POPULATION 36
5.5 RESTRAINTS 36
5.5.1 STRINGENT REGULATORY APPROVAL PROCESS FOR REGENERATIVE MEDICINES 36
5.5.2 ETHICAL ISSUES WITH THE USE OF EMBRYONIC STEM CELL FOR RESEARCH AND DEVELOPMENT 37
5.6 OPPORTUNITIES 37
5.6.1 RISING DEMAND FOR ORGAN TRANSPLANTATION 37
5.6.2 STRONG PRODUCT PIPELINE TO DRIVE THE MARKET 37
5.6.3 INCREASE IN R&D SPENDING 38
5.7 CHALLENGES 39
5.7.1 LACK OF CLEAR REGULATORY GUIDELINES 39
5.7.2 HIGH COSTS INCURRED IN STEM CELL PROCESSING 39
 
6 GLOBAL REGENERATIVE MEDICINES MARKET, BY PRODUCT 40
6.1 INTRODUCTION 41
6.2 CELL-BASED PRODUCTS 42
6.2.1 AUTOLOGOUS CELL-BASED PRODUCTS 45
6.2.2 ALLOGENEIC CELL-BASED PRODUCTS 47
6.3 ACELLULAR PRODUCTS 48
 
7 GLOBAL REGENERATIVE MEDICINES MARKET, BY THERAPY 50
7.1 INTRODUCTION 51
7.2 CELL THERAPY 52
7.3 GENE THERAPY 54
7.4 TISSUE ENGINEERING 55
7.5 IMMUNOTHERAPY 56
 
8 REGENERATIVE MEDICINES MARKET, BY APPLICATION 58
8.1 INTRODUCTION 59
8.2 ORTHOPEDIC & MUSCULOSKELETAL SPINE 61
8.3 DERMATOLOGY 62
8.4 CARDIOVASCULAR 64
8.5 CENTRAL NERVOUS SYSTEM 65
8.6 ONCOLOGY 67
8.7 DIABETES 68
8.8 OTHERS 70
 
9 GLOBAL REGENERATIVE MEDICINES MARKET, BY REGION 71
9.1 INTRODUCTION 72
9.2 NORTH AMERICA 74
9.2.1 U.S. 79
9.2.2 CANADA 83
9.3 EUROPE 86
9.3.1 GERMANY 93
9.3.2 UK 96
9.3.3 FRANCE 100
9.3.4 ITALY 103
9.3.5 SPAIN 107
9.3.6 REST OF EUROPE (ROE) 110
9.4 ASIA-PACIFIC 114
9.5 REST OF THE WORLD (ROW) 121
 
10 COMPETITIVE LANDSCAPE 126
10.1 OVERVIEW 126
10.2 MARKET SHARE ANALYSIS 127
10.3 COMPETITIVE SITUATION AND TRENDS 128
10.3.1 NEW PRODUCT LAUNCHES 129
10.3.2 ACQUISITIONS 130
10.3.3 REGULATORY APPROVALS 131
10.3.4 PARTNERSHIPS 131
 
11 COMPANY PROFILE 133
(Overview, Financial*, Products & Services, Strategy, and Developments)
11.1 INTRODUCTION 133
11.2 VERTEX PHARMACEUTICALS INCORPORATED 134
11.3 CELGENE CORPORATION 136
11.4 ACELITY (KCI LICENSING) 138
11.5 NUVASIVE, INC. 140
11.6 ORGANOGENESIS INC. 142
11.7 JAPAN TISSUE ENGINEERING CO., LTD (SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION) 144
11.8 VERICEL CORPORATION 145
11.9 CYTORI THERAPEUTICS INC. 147
11.10 STEMCELLS, INC. 149
11.11 ADVANTAGENE, INC. 150
11.12 MESOBLAST LTD 151
*Details might not be captured in case of unlisted companies.
 
12 APPENDIX 153
12.1 INSIGHTS FROM INDUSTRY EXPERTS 153
12.2 DISCUSSION GUIDE 153
12.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 155
12.4 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 156
12.5 AVAILABLE CUSTOMIZATIONS 158
12.6 RELATED REPORTS 158
 
List of Tables
TABLE 1 GLOBAL REGENERATIVE MEDICINES MARKET SIZE, BY PRODUCT,  
2014–2021 (USD BILLION) 42
TABLE 2 CELL-BASED REGENERATIVE MEDICINES MARKET SIZE, BY TYPE,  
2014–2021 (USD BILLION) 44
TABLE 3 CELL-BASED REGENERATIVE MEDICINES MARKET SIZE, BY REGION,  
2014–2021 (USD BILLION) 45
TABLE 4 AUTOLOGOUS REGENERATIVE MEDICINES MARKET SIZE, BY REGION,  
2014–2021 (USD BILLION) 46
TABLE 5 ALLOGENEIC REGENERATIVE MEDICINES MARKET SIZE, BY REGION,  
2014–2021 (USD BILLION) 48
TABLE 6 ACELLULAR REGENERATIVE MEDICINES MARKET SIZE, BY REGION,  
2014–2021 (USD BILLION) 49
TABLE 7 GLOBAL REGENERATIVE MEDICINES MARKET, BY THERAPY, 
2014–2021 (USD BILLION) 51
TABLE 8 CELL THERAPY MARKET, BY REGION, 2014-2021 (USD BILLION) 53
TABLE 9 GENE THERAPY MARKET, BY REGION, 2014-2021 (USD BILLION) 54
TABLE 10 TISSUE ENGINEERING MARKET, BY REGION, 2014-2021 (USD BILLION) 56
TABLE 11 IMMUNOTHERAPY MARKET, BY REGION, 2014-2021 (USD BILLION) 57
TABLE 12 REGENERATIVE MEDICINES MARKET SIZE, BY APPLICATION, 
2014–2021 (USD BILLION) 60
TABLE 13 ORTHOPEDIC & MUSCULOSKELETAL SPINE MARKET, BY REGION,  
2014–2021 (USD BILLION) 62
TABLE 14 DERMATOLOGY MARKET, BY REGION, 2014–2021 (USD BILLION) 63
TABLE 15 CARDIOVASCULAR MARKET, BY REGION, 2014–2021 (USD BILLION) 65
TABLE 16 CENTRAL NERVOUS SYSTEM MARKET, BY REGION, 2014–2021 (USD BILLION) 66
TABLE 17 ONCOLOGY MARKET, BY REGION, 2014–2021 (USD BILLION) 68
TABLE 18 DIABETES MARKET, BY REGION, 2014–2021 (USD BILLION) 69
TABLE 19 OTHERS MARKET, BY REGION, 2014–2021 (USD BILLION) 70
TABLE 20 GLOBAL REGENERATIVE MEDICINES MARKET, BY REGION, 
2014–2021 (USD BILLION) 73
TABLE 21 NORTH AMERICA REGENERATIVE MEDICINES MARKET, BY GEOGRAPHY,  
2014–2021 (USD BILLION) 76
TABLE 22 NORTH AMERICA REGENERATIVE MEDICINES MARKET, BY PRODUCT,  
2014–2021 (USD BILLION) 76
TABLE 23 NORTH AMERICA CELL-BASED PRODUCTS MARKET, BY TYPE, 
2014–2021 (USD BILLION) 77
TABLE 24 NORTH AMERICA REGENERATIVE MEDICINES MARKET, BY APPLICATION,  
2014–2021 (USD BILLION) 78
TABLE 25 NORTH AMERICA REGENERATIVE MEDICINES MARKET, BY THERAPY,  
2014–2021 (USD BILLION) 79
TABLE 26 U.S. REGENERATIVE MEDICINES MARKET, BY PRODUCT, 
2014–2021 (USD BILLION) 80
TABLE 27 U.S. CELL-BASED PRODUCTS MARKET, BY TYPE, 2014–2021 (USD BILLION) 80
TABLE 28 U.S. REGENERATIVE MEDICINES MARKET, BY APPLICATION, 
2014–2021 (USD BILLION) 81
TABLE 29 U.S. REGENERATIVE MEDICINES MARKET, BY THERAPY, 
2014–2021 (USD BILLION) 82
TABLE 30 CANADA REGENERATIVE MEDICINES MARKET, BY PRODUCT, 
2014–2021 (USD BILLION) 83
TABLE 31 CANADA CELL-BASED PRODUCTS MARKET, BY TYPE, 2014–2021 (USD BILLION) 84
TABLE 32 CANADA REGENERATIVE MEDICINES MARKET, BY APPLICATION,  
2014–2021 (USD BILLION) 85
TABLE 33 CANADA REGENERATIVE MEDICINES MARKET, BY THERAPY, 
2014–2021 (USD BILLION) 86
TABLE 34 EUROPE REGENERATIVE MEDICINES MARKET, BY GEOGRAPHY,  
2014–2021 (USD BILLION) 89
TABLE 35 EUROPE REGENERATIVE MEDICINES MARKET, BY PRODUCT, 
2014–2021 (USD BILLION) 90
TABLE 36 EUROPE CELL-BASED PRODUCTS MARKET, BY TYPE, 2014–2021 (USD BILLION) 90
TABLE 37 EUROPE REGENERATIVE MEDICINES MARKET, BY APPLICATION,  
2014–2021 (USD BILLION) 91
TABLE 38 EUROPE REGENERATIVE MEDICINES MARKET, BY THERAPY, 
2014–2021 (USD BILLION) 92
TABLE 39 GERMANY REGENERATIVE MEDICINES MARKET, BY PRODUCT,  
2014–2021 (USD BILLION) 93
TABLE 40 GERMANY CELL-BASED PRODUCTS MARKET, BY TYPE, 2014–2021 (USD BILLION) 93
TABLE 41 GERMANY REGENERATIVE MEDICINES MARKET, BY APPLICATION,  
2014–2021 (USD BILLION) 95
TABLE 42 GERMANY REGENERATIVE MEDICINES MARKET, BY THERAPY, 
2014–2021 (USD BILLION) 96
TABLE 43 UK REGENERATIVE MEDICINES MARKET, BY PRODUCT, 2014–2021 (USD BILLION) 97
TABLE 44 UK CELL-BASED PRODUCTS MARKET, BY TYPE, 2014–2021 (USD BILLION) 97
TABLE 45 UK REGENERATIVE MEDICINES MARKET, BY APPLICATION,  
2014–2021 (USD BILLION) 98
TABLE 46 UK REGENERATIVE MEDICINES MARKET, BY THERAPY, 2014–2021 (USD BILLION) 99
TABLE 47 FRANCE REGENERATIVE MEDICINES MARKET, BY PRODUCT, 
2014–2021 (USD BILLION) 100
TABLE 48 FRANCE CELL-BASED PRODUCTS MARKET, BY TYPE, 2014–2021 (USD BILLION) 100
TABLE 49 FRANCE REGENERATIVE MEDICINES MARKET, BY APPLICATION,  
2014–2021 (USD BILLION) 102
TABLE 50 FRANCE REGENERATIVE MEDICINES MARKET, BY THERAPY, 
2014–2021 (USD BILLION) 103
TABLE 51 ITALY REGENERATIVE MEDICINES MARKET, BY PRODUCT, 
2014–2021 (USD BILLION) 104
TABLE 52 ITALY CELL-BASED PRODUCTS MARKET, BY TYPE, 2014–2021 (USD BILLION) 104
TABLE 53 ITALY REGENERATIVE MEDICINES MARKET, BY APPLICATION,  
2014–2021 (USD BILLION) 105
TABLE 54 ITALY REGENERATIVE MEDICINES MARKET, BY THERAPY, 
2014–2021 (USD BILLION) 106
TABLE 55 SPAIN REGENERATIVE MEDICINES MARKET, BY PRODUCT, 
2014–2021 (USD BILLION) 107
TABLE 56 SPAIN CELL-BASED PRODUCTS MARKET, BY TYPE, 2014–2021 (USD BILLION) 107
TABLE 57 SPAIN REGENERATIVE MEDICINES MARKET, BY APPLICATION,  
2014–2021 (USD BILLION) 109
TABLE 58 SPAIN REGENERATIVE MEDICINES MARKET, BY THERAPY, 
2014–2021 (USD BILLION) 110
TABLE 59 REST OF EUROPE(ROE) REGENERATIVE MEDICINES MARKET, 
BY PRODUCT,  2014–2021 (USD BILLION) 111
TABLE 60 REST OF EUROPE(ROE) CELL-BASED PRODUCTS MARKET, BY TYPE,  
2014–2021 (USD BILLION) 111
TABLE 61 REST OF EUROPE (ROE) REGENERATIVE MEDICINES MARKET, 
BY APPLICATION,  2014–2021 (USD BILLION) 112
TABLE 62 REST OF EUROPE (ROE) REGENERATIVE MEDICINES MARKET, 
BY THERAPY,  2014–2021 (USD BILLION) 113
TABLE 63 ASIA-PACIFIC REGENERATIVE MEDICINES MARKET, BY PRODUCT,  
2014–2021 (USD BILLION) 117
TABLE 64 ASIA-PACIFIC CELL-BASED PRODUCTS MARKET, BY TYPE, 
2014–2021 (USD BILLION) 117
TABLE 65 ASIA-PACIFIC REGENERATIVE MEDICINES MARKET, BY APPLICATION,  
2014–2021 (USD BILLION) 119
TABLE 66 ASIA-PACIFIC REGENERATIVE MEDICINES MARKET, BY THERAPY,  
2013–2021 (USD BILLION) 120
TABLE 67 ROW REGENERATIVE MEDICINES MARKET, BY PRODUCT, 
2014–2021 (USD BILLION) 122
TABLE 68 ROW CELL-BASED PRODUCTS MARKET, BY TYPE, 2014–2021 (USD BILLION) 122
TABLE 69 ROW REGENERATIVE MEDICINES MARKET, BY APPLICATION, 
2014–2021 (USD BILLION) 124
TABLE 70 ROW REGENERATIVE MEDICINES MARKET, BY THERAPY, 
2014–2021 (USD BILLION) 125
TABLE 71 NEW PRODUCT LAUNCHES, 2013–2016 129
TABLE 72 ACQUISITIONS, 2014–2016 130
TABLE 73 REGULATORY APPROVALS, 2013–2016 131
TABLE 74 PARTNERSHIPS, 2016 131
TABLE 75 AGREEMENTS, 2013–2016 132
 
List of Figures
FIGURE 1 RESEARCH DESIGN 18
FIGURE 2 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 20
FIGURE 3 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 20
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,  
AND REGION 21
FIGURE 5 DATA TRIANGULATION METHODOLOGY 22
FIGURE 6 REGENERATIVE MEDICINES MARKET, BY PRODUCT (2016 VS. 2021) 25
FIGURE 7 REGENERATIVE MEDICINES MARKET, BY THERAPY, 2016 VS. 2021 26
FIGURE 8 ORTHOPEDIC & MUSCULOSKELETAL SPINE FORM THE LARGEST APPLICATION SEGMENT 26
FIGURE 9 GLOBAL REGENERATIVE MEDICINES MARKET TO WITNESS HIGH GROWTH DURING THE FORECAST PERIOD 28
FIGURE 10 CELL THERAPY SEGMENT DOMINATES THE REGENERATIVE MEDICINES MARKET 29
FIGURE 11 ASIA TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 30
FIGURE 12 REGENERATIVE MEDICINES MARKET SEGMENTATION 31
FIGURE 13 REGENERATIVE MEDICINES MARKET SEGMENTATION, BY THERAPY 32
FIGURE 14 REGENERATIVE MEDICINES MARKET SEGMENTATION, BY PRODUCT 32
FIGURE 15 REGENERATIVE MEDICINES MARKET SEGMENTATION, BY APPLICATION 33
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 34
FIGURE 17 GLOBAL REGENERATIVE MEDICINES MARKET, BY PRODUCT 41
FIGURE 18 CELL-BASED PRODUCTS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE GLOBAL REGENERATIVE MEDICINES MARKET IN 2015 42
FIGURE 19 CELL-BASED PRODUCTS, BY TYPE 43
FIGURE 20 ALLOGENEIC SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE CELL-BASED REGENERATIVE MEDICINES MARKET IN 2015 43
FIGURE 21 NORTH AMERICA ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE OF THE CELL-BASED REGENERATIVE MEDICINES MARKET IN 2016 44
FIGURE 22 NORTH AMERICA ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE OF THE AUTOLOGOUS REGENERATIVE MEDICINES MARKET IN 2016 46
FIGURE 23 NORTH AMERICA TO ACCOUNT FOR THE LARGEST SHARE OF ALLOGENEIC REGENERATIVE MEDICINES MARKET IN 2016 47
FIGURE 24 ASIA-PACIFIC EXPECTED TO BE THE FASTEST-GROWING SEGMENT OF THE ACELLULAR REGENERATIVE MEDICINES MARKET DURING THE FORECAST PERIOD 49
FIGURE 25 GLOBAL REGENERATIVE MEDICINES MARKET, BY THERAPY 51
FIGURE 26 THE CELL THERAPY SEGMENT TO LEAD THE GLOBAL REGENERATIVE MEDICINES MARKET DURING THE FORECAST PERIOD 52
FIGURE 27 CELL THERAPY MARKET, BY REGION, 2016 & 2021 (USD BILLION) 53
FIGURE 28 GENE THERAPY MARKET, BY REGION, 2016 & 2021 (USD BILLION) 54
FIGURE 29 TISSUE ENGINEERING MARKET, BY REGION, 2016 & 2021 (USD BILLION) 55
FIGURE 30 IMMUNOTHERAPY MARKET, BY REGION, 2016 & 2021 (USD BILLION) 57
FIGURE 31 REGENERATIVE MEDICINES MARKET SEGMENTATION, BY APPLICATION 59
FIGURE 32 ORTHOPEDIC & MUSCULOSKELETAL SPINE SEGMENT DOMINATED THE REGENERATIVE MEDICINE APPLICATION MARKET IN 2015 60
FIGURE 33 NORTH AMERICA ACCOUNTED FOR THE LARGEST SHARE OF THE GLOBAL REGENERATIVE MEDICINES MARKET FOR ORTHOPEDIC & MUSCULOSKELETAL SPINE IN 2015 61
FIGURE 34 NORTH AMERICA DOMINATED THE REGENERATIVE MEDICINES MARKET FOR DERMATOLOGY IN 2015 63
FIGURE 35 ASIA-PACIFIC IS THE FASTEST GROWING REGION IN THE GLOBAL REGENERATIVE MEDICINES MARKET FOR CARDIOVASCULAR APPLICATIONS 64
FIGURE 36 NORTH AMERICA DOMINATED THE REGENERATIVE MEDICINES MARKET FOR CENTRAL NERVOUS SYSTEM APPLICATIONS IN 2015 66
FIGURE 37 ASIA-PACIFIC IS THE FASTEST GROWING REGION IN THE GLOBAL REGENERATIVE MEDICINES MARKET FOR ONCOLOGY APPLICATION 67
FIGURE 38 ASIA-PACIFIC IS THE FASTEST GROWING REGION IN THE GLOBAL REGENERATIVE MEDICINES MARKET FOR DIABETES APPLICATION 69
FIGURE 39 NORTH AMERICA DOMINATED THE REGENERATIVE MEDICINES MARKET FOR OTHER APPLICATIONS IN 2015 70
FIGURE 40 REGIONAL SNAPSHOT (2015) 72
FIGURE 41 THE REGENERATIVE MEDICINES MARKET IN THE ASIA-PACIFIC REGION IS PROJECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 73
FIGURE 42 NORTH AMERICA REGENERATIVE MEDICINES MARKET SNAPSHOT 75
FIGURE 43 CELL-BASED PRODUCTS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICA REGENERATIVE MEDICINES MARKET IN 2015 76
FIGURE 44 ORTHOPEDIC & MUSCULOSKELETAL SPINE APPLICATION SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICA REGENERATIVE MEDICINES MARKET IN 2015 77
FIGURE 45 CELL THERAPY SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICA REGENERATIVE MEDICINES THERAPY MARKET IN 2015 78
FIGURE 46 CELL-BASED PRODUCTS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE U.S. REGENERATIVE MEDICINES MARKET IN 2015 79
FIGURE 47 ORTHOPEDIC & MUSCULOSKELETAL SPINE APPLICATION SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE U.S. REGENERATIVE MEDICINES MARKET 
IN 2015 81
FIGURE 48 CELL THERAPY SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE U.S. REGENERATIVE MEDICINES THERAPY MARKET 82
FIGURE 49 CELL-BASED PRODUCTS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE CANADA REGENERATIVE MEDICINES MARKET IN 2015 83
FIGURE 50 ORTHOPEDIC & MUSCULOSKELETAL SPINE APPLICATION SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE CANADA REGENERATIVE MEDICINES MARKET 
IN 2015 84
FIGURE 51 CELL THERAPY SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE CANADA REGENERATIVE MEDICINES THERAPY MARKET 85
FIGURE 52 EUROPE REGENERATIVE MEDICINES MARKET SNAPSHOT 88
FIGURE 53 AMONG PRODUCTS, THE CELL-BASED PRODUCTS SEGMENT LED THE EUROPE REGENERATIVE MEDICINES MARKET IN 2015 89
FIGURE 54 AMONG APPLICATIONS, THE ORTHOPEDIC & MUSCULOSKELETAL SPINE SEGMENT ACCOUNTED FOR THE LARGEST SHARE IN THE EUROPE REGENERATIVE MEDICINES MARKET IN 2015 91
FIGURE 55 THE CELL THERAPY SEGMENT LED THE EUROPE REGENERATIVE MEDICINES MARKET IN 2015 92
FIGURE 56 CELL-BASED PRODUCTS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE GERMANY REGENERATIVE MEDICINES MARKET IN 2015 93
FIGURE 57 AMONG APPLICATIONS, THE ORTHOPEDIC & MUSCULOSKELETAL SPINE SEGMENT ACCOUNTED FOR THE LARGEST SHARE IN THE GERMANY REGENERATIVE MEDICINES MARKET IN 2015 94
FIGURE 58 THE CELL THERAPY SEGMENT LED THE GERMANY REGENERATIVE MEDICINES MARKET IN 2015 95
FIGURE 59 CELL-BASED PRODUCTS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE U.K. REGENERATIVE MEDICINES MARKET IN 2015 96
FIGURE 60 AMONG APPLICATIONS, THE ORTHOPEDIC & MUSCULOSKELETAL SPINE SEGMENT ACCOUNTED FOR THE LARGEST SHARE IN THE UK REGENERATIVE MEDICINES MARKET IN 2015 98
FIGURE 61 THE CELL THERAPY SEGMENT LED THE UK REGENERATIVE MEDICINES MARKET 
IN 2015 99
FIGURE 62 CELL-BASED PRODUCTS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE FRANCE REGENERATIVE MEDICINES MARKET IN 2015 100
FIGURE 63 AMONG APPLICATIONS, THE ORTHOPEDIC & MUSCULOSKELETAL SPINE SEGMENT ACCOUNTED FOR THE LARGEST SHARE IN THE FRANCE REGENERATIVE MEDICINES MARKET IN 2015 101
FIGURE 64 THE CELL THERAPY SEGMENT LED THE FRANCE REGENERATIVE MEDICINES MARKET IN 2015 102
FIGURE 65 CELL-BASED PRODUCTS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ITALY REGENERATIVE MEDICINES MARKET IN 2015 103
FIGURE 66 AMONG APPLICATIONS, THE ORTHOPEDIC & MUSCULOSKELETAL SPINE SEGMENT ACCOUNTED FOR THE LARGEST SHARE IN THE ITALY REGENERATIVE MEDICINES MARKET IN 2015 105
FIGURE 67 THE CELL THERAPY SEGMENT LED THE ITALY REGENERATIVE MEDICINES MARKET IN 2015 106
FIGURE 68 CELL-BASED PRODUCTS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE  SPAIN REGENERATIVE MEDICINES MARKET IN 2015 107
FIGURE 69 AMONG APPLICATIONS, THE ORTHOPEDIC & MUSCULOSKELETAL SPINE SEGMENT ACCOUNTED FOR THE LARGEST SHARE IN THE SPAIN REGENERATIVE MEDICINES MARKET IN 2015 108
FIGURE 70 THE CELL THERAPY SEGMENT LED THE SPAIN REGENERATIVE MEDICINES MARKET IN 2015 109
FIGURE 71 CELL-BASED PRODUCTS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE  REST OF THE EUROPE (ROE) REGENERATIVE MEDICINES MARKET IN 2015 110
FIGURE 72 AMONG APPLICATIONS, THE ORTHOPEDIC & MUSCULOSKELETAL SPINE SEGMENT ACCOUNTED FOR THE LARGEST SHARE IN THE REST OF EUROPE (ROE) REGENERATIVE MEDICINES MARKET IN 2015 112
FIGURE 73 THE CELL THERAPY SEGMENT LED THE REST OF EUROPE (ROE) REGENERATIVE MEDICINES MARKET IN 2015 113
FIGURE 74 ASIA-PACIFIC REGENERATIVE MEDICINES MARKET SNAPSHOT 116
FIGURE 75 AMONG PRODUCTS, THE CELL-BASED PRODUCTS SEGMENT ACCOUNTED FOR THE LARGEST SHARE IN THE ASIA-PACIFIC REGENERATIVE MEDICINES MARKET 
IN 2015 117
FIGURE 76 AMONG APPLICATIONS, THE ORTHOPEDIC & MUSCULOSKELETAL SPINE SEGMENT ACCOUNTED FOR THE LARGEST SHARE IN THE ASIA-PACIFIC REGENERATIVE MEDICINES MARKET IN 2015 118
FIGURE 77 THE CELL THERAPY SEGMENT ACCOUNTED FOR THE LARGEST SHARE IN THE ASIA-PACIFIC REGENERATIVE MEDICINES IN 2015 119
FIGURE 78 THE CELL-BASED PRODUCTS SEGMENT ACCOUNTED FOR THE LARGEST SHARE IN THE ROW REGENERATIVE MEDICINES MARKET IN 2015 122
FIGURE 79 AMONG APPLICATIONS, THE ORTHOPEDIC & MUSCULOSKELETAL SPINE SEGMENT ACCOUNTED FOR THE LARGEST SHARE IN THE ROW REGENERATIVE MEDICINES MARKET IN 2015 123
FIGURE 80 THE CELL THERAPY SEGMENT ACCOUNTED FOR THE LARGEST SHARE IN THE ROW REGENERATIVE MEDICINES MARKET IN 2015 124
FIGURE 81 LEADING MARKET PLAYERS ADOPTED BOTH ORGANIC AND INORGANIC GROWTH STRATEGIES OVER THE LAST FOUR YEARS (2013–2016) 126
FIGURE 82 GLOBAL REGENERATIVE MEDICINES MARKET SHARE ANALYSIS, 
BY KEY PLAYER, 2015 127
FIGURE 83 BATTLE FOR MARKET SHARE: NEW PRODUCT LAUNCHES & PRODUCT ENHANCEMENTS IS THE KEY STRATEGY 128
FIGURE 84 GEOGRAPHIC REVENUE SNAPSHOT (2015) 133
FIGURE 85 VERTEX PHARMACEUTICALS INCORPORATED: COMPANY SNAPSHOT 134
FIGURE 86 CELGENE CORPORATION: COMPANY SNAPSHOT 136
FIGURE 87 ACELITY (KCI LICENSING): COMPANY SNAPSHOT 138
FIGURE 88 NUVASIVE, INC.: COMPANY SNAPSHOT 140
FIGURE 89 VERICEL CORPORATION: COMPANY SNAPSHOT 145
FIGURE 90 CYTORI THERAPEUTICS INC.: COMPANY SNAPSHOT 147
FIGURE 91 STEMCELLS, INC.: COMPANY SNAPSHOT 149
 

关于我们|联系我们|常见问题|服务项目|购买流程
2005-2013 All rights reserved.京ICP备05069564号-4 京公网安备110108 02010359号
全国服务热线:400-009-0050北京:010-82863481上海:021-64871266

在线客服系统